ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated…
-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- -- Company to hold conference call at 8:30 a.m. Eastern Time -- SAN CARLOS, Calif., Oct. 08, 2021…